In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.Requests for Special Authorization will be considered for patients who: Requests for Special Authorization will also be considered for patients who: Requests for Special Authorization are considered for patients:Requests for special authorization are considered for the following:Requests for special authorization will be considered for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults.Requests for special authorization will be considered for sclerosing of varicose veins in patients with complications (e.g. - Patients with moderately to severely active Crohn’s disease who have had an inadequate response , or intolerance to: A 6 week trial of sulfasalazine if there is mild active Crohn’s disease involving the colon OR oral or intravenous corticosteroids for more severe Crohn’s disease AND A trial of immunosuppresants (i.e., azathioprine, 6-mercaptopurine or methotrexate) for a minimum of 3 months unless the severity of the disease requires earlier use of TNF inhibitors. I went through similar trials a couple of years ago when my local carrier dropped my pharmacy the week of selecting my advantage plan. inhaled steroids) and still require short-acting bronchodilator more than twice daily - patients with severe COPD (chronic obstructive pulmonary disorder) with a reversible component, where symptoms have not responded to first-line therapy, e.g. Galexos containing regimens are not eligible for coverage for the treatment of hepatitis C virus (CHC) infection genotypes 1 - 4. NSAIDs and standard analgesic therapy), unless contraindicated.Requests for special authorization are considered for clients who meet the following criteria: HIV positive patients who have failed traditional antiretroviral therapy, defined as those patients who have failed at least 2 susceptible antiretrovirals and whose viral load is more than 5000Requests for special authorization will be considered for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced ormetastatic breast cancer in combination with: - an aromatase inhibitor as initial endocrine-based therapy; or - fulvestrant in patients with disease progression after prior endocrine therapy. tretinoin, benzoyl peroxide or topical clindamycin) - the treatment of acne vulgaris and/or papular acne if the patient is intolerant or allergic to other therapies (e.g. Patient is an adult with a confirmed diagnosis of Heterozygous Familial Hypercholesterolemia, as defined below.A. Medication must have been prescribed by, or in consultation with a rheumatologist.Requests for Special Authorization will be considered for: - patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin when metformin used alone, with diet and exercise, does not provide adequate glycemic control - patients with type 2 diabetes mellitus to improve glycemic control in combination with sulfonylurea when sulfonylurea used alone, with diet and exercise, does not provide adequate glycemic control - patients with type 2 diabetes mellitus to improve glycemic control in combination with premixed or long/intermediate acting insulin (with or without metformin) when premixed or long/intermediate acting insulin (with or without metformin) used alone, with diet and exercise, do not provide adequate glycemic control - patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these two agents, with diet and exercise, does not provide adequate glycemic controlRequests for special authorization will be considered for the topical treatment of facial erythema of rosacea in adults 18 years of age or older.Requests for Special Authorization for Opsumit are considered for the:Requests for Special Authorization are considered for the treatment of symptoms of seasonal grass pollen allergic rhinitis with or without conjunctivitis.Requests for special authorization are considered for: - Pediatric Growth Hormone Deficiency - Patients who have growth failure due to growth hormone inadequacy.